$1.12
+0.01
(+0.9%)▲
1.79%
Downside
Day's Volatility :2.65%
Upside
0.88%
11.6%
Downside
52 Weeks Volatility :33.99%
Upside
25.33%
Period | Enzo Biochem Inc | Index (Russel 2000) |
---|---|---|
3 Months | -0.88% | 0.0% |
6 Months | -15.79% | 0.0% |
1 Year | -23.81% | 0.0% |
3 Years | -69.57% | -22.3% |
Market Capitalization | 57.6M |
Book Value | $1.35 |
Earnings Per Share (EPS) | -0.35 |
PEG Ratio | 0.0 |
Wall Street Target Price | 5.5 |
Profit Margin | 134.17% |
Operating Margin TTM | -25.47% |
Return On Assets TTM | -12.77% |
Return On Equity TTM | -39.9% |
Revenue TTM | 33.3M |
Revenue Per Share TTM | 0.66 |
Quarterly Revenue Growth YOY | 7.199999999999999% |
Gross Profit TTM | 11.6M |
EBITDA | -15.4M |
Diluted Eps TTM | -0.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 391.07%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 104.7M | ↓ 2.87% |
Net Income | -10.3M | ↑ 312.18% |
Net Profit Margin | -9.86% | ↓ 7.54% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 81.2M | ↓ 22.48% |
Net Income | -98.8M | ↑ 857.09% |
Net Profit Margin | -121.7% | ↓ 111.84% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 76.0M | ↓ 6.34% |
Net Income | -33.9M | ↓ 65.69% |
Net Profit Margin | -44.58% | ↑ 77.12% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 117.7M | ↑ 54.87% |
Net Income | 3.4M | ↓ 110.11% |
Net Profit Margin | 2.91% | ↑ 47.49% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 107.1M | ↓ 9.05% |
Net Income | -22.6M | ↓ 759.21% |
Net Profit Margin | -21.09% | ↓ 24.0% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 31.1M | ↓ 70.99% |
Net Income | 20.3M | ↓ 189.86% |
Net Profit Margin | 65.32% | ↑ 86.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.3M | ↓ 10.6% |
Net Income | -10.7M | ↓ 14.26% |
Net Profit Margin | -65.22% | ↑ 2.78% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.1M | ↓ 1.41% |
Net Income | -14.7M | ↑ 38.22% |
Net Profit Margin | -91.44% | ↓ 26.22% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 31.1M | ↑ 92.84% |
Net Income | 20.3M | ↓ 237.74% |
Net Profit Margin | 65.32% | ↑ 156.76% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.8M | ↓ 74.87% |
Net Income | -6.6M | ↓ 132.61% |
Net Profit Margin | -84.76% | ↓ 150.08% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.6M | ↑ 9.57% |
Net Income | -3.1M | ↓ 53.73% |
Net Profit Margin | -35.79% | ↑ 48.97% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.0M | ↓ 6.21% |
Net Income | -3.0M | ↓ 1.34% |
Net Profit Margin | -37.65% | ↓ 1.86% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 101.7M | ↓ 5.58% |
Total Liabilities | 20.5M | ↑ 9.29% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 106.6M | ↑ 4.9% |
Total Liabilities | 20.6M | ↑ 0.36% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 112.5M | ↑ 5.53% |
Total Liabilities | 54.2M | ↑ 162.75% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 113.7M | ↑ 1.02% |
Total Liabilities | 45.1M | ↓ 16.71% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 95.9M | ↓ 15.69% |
Total Liabilities | 41.4M | ↓ 8.23% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 121.9M | ↑ 27.15% |
Total Liabilities | 43.4M | ↑ 4.89% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 76.5M | ↓ 10.27% |
Total Liabilities | 43.6M | ↑ 8.49% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 72.1M | ↓ 5.74% |
Total Liabilities | 53.1M | ↑ 21.8% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 121.9M | ↑ 69.13% |
Total Liabilities | 43.4M | ↓ 18.28% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 106.3M | ↓ 12.78% |
Total Liabilities | 32.0M | ↓ 26.22% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 99.1M | ↓ 6.8% |
Total Liabilities | 28.3M | ↓ 11.65% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 93.5M | ↓ 5.66% |
Total Liabilities | 24.4M | ↓ 13.65% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.7M | ↑ 1234.15% |
Investing Cash Flow | -1.9M | ↑ 11.15% |
Financing Cash Flow | 559.0K | ↓ 133.49% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.8M | ↓ 275.72% |
Investing Cash Flow | -8.1M | ↑ 318.0% |
Financing Cash Flow | 4.2M | ↑ 650.09% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.2M | ↓ 457.45% |
Investing Cash Flow | -2.2M | ↓ 73.3% |
Financing Cash Flow | 7.0M | ↑ 66.97% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 387.0K | ↓ 102.25% |
Investing Cash Flow | -34.5M | ↑ 1489.72% |
Financing Cash Flow | -242.0K | ↓ 103.46% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.6M | ↓ 4386.82% |
Investing Cash Flow | 25.2M | ↓ 173.12% |
Financing Cash Flow | -241.0K | ↓ 0.41% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -37.0M | ↑ 122.88% |
Investing Cash Flow | 99.0M | ↑ 292.42% |
Financing Cash Flow | -1.1M | ↑ 366.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.2M | ↓ 28.7% |
Investing Cash Flow | -869.0K | ↑ 33.28% |
Financing Cash Flow | -62.0K | ↓ 34.74% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.1M | ↓ 18.46% |
Investing Cash Flow | -666.0K | ↓ 23.36% |
Financing Cash Flow | 3.3M | ↓ 5377.42% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.4M | ↑ 164.62% |
Investing Cash Flow | -254.0K | ↓ 61.86% |
Financing Cash Flow | -518.0K | ↓ 115.83% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -13.4M | ↑ 0.0% |
Investing Cash Flow | -254.0K | ↑ 0.0% |
Financing Cash Flow | -518.0K | ↑ 0.0% |
Sell
Neutral
Buy
Enzo Biochem Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Enzo Biochem Inc | 4.67% | -15.79% | -23.81% | -69.57% | -67.16% |
![]() Idexx Laboratories, Inc. | 1.13% | -16.13% | -1.02% | -30.71% | 76.78% |
![]() Agilent Technologies Inc. | 2.42% | -8.11% | 18.01% | -22.8% | 84.96% |
![]() Thermo Fisher Scientific, Inc. | 4.08% | 2.29% | 14.99% | 7.41% | 109.35% |
![]() Danaher Corp. | 1.1% | 4.75% | 17.79% | -19.33% | 91.02% |
![]() Iqvia Holdings Inc. | 5.86% | -6.0% | 10.99% | -8.08% | 60.05% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Enzo Biochem Inc | NA | NA | 0.0 | 0.0 | -0.4 | -0.13 | NA | 1.35 |
![]() Idexx Laboratories, Inc. | 46.49 | 46.49 | 5.05 | 10.51 | 0.63 | 0.23 | NA | 19.16 |
![]() Agilent Technologies Inc. | 28.76 | 28.76 | 2.99 | 5.24 | 0.25 | 0.08 | 0.01 | 20.53 |
![]() Thermo Fisher Scientific, Inc. | 37.6 | 37.6 | 2.26 | 21.75 | 0.14 | 0.05 | 0.0 | 124.17 |
![]() Danaher Corp. | 48.58 | 48.58 | 2.63 | 7.58 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Iqvia Holdings Inc. | 32.24 | 32.24 | 1.22 | 11.2 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Enzo Biochem Inc | Buy | $57.6M | -67.16% | NA | 134.17% |
![]() Idexx Laboratories, Inc. | Buy | $38.9B | 76.78% | 46.49 | 22.34% |
![]() Agilent Technologies Inc. | Buy | $39.8B | 84.96% | 28.76 | 21.75% |
![]() Thermo Fisher Scientific, Inc. | Buy | $233.5B | 109.35% | 37.6 | 14.69% |
![]() Danaher Corp. | Buy | $192.3B | 91.02% | 48.58 | 17.83% |
![]() Iqvia Holdings Inc. | Buy | $45.2B | 60.05% | 32.24 | 9.39% |
Insights on Enzo Biochem Inc
Revenue is down for the last 2 quarters, 8.55M → 8.02M (in $), with an average decrease of 6.2% per quarter
Netprofit is up for the last 3 quarters, -6.61M → -3.02M (in $), with an average increase of 58.8% per quarter
In the last 1 year, Agilent Technologies Inc. has given 18.0% return, outperforming this stock by 41.8%
In the last 3 years, Enzo Biochem Inc has experienced a drawdown of -69.6%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 46.8%
Harbert Fund Advisors Inc
Renaissance Technologies Corp
Vanguard Group Inc
BlackRock Inc
Dimensional Fund Advisors, Inc.
Geode Capital Management, LLC
enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.
Organization | Enzo Biochem Inc |
Employees | 179 |
CEO | Ms. Kara Cannon |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.12
+0.9%
Keyarch Acquisition Corp
$1.12
+0.9%
Connexa Sports Technologies Inc
$1.12
+0.9%
Us Value Etf
$1.12
+0.9%
First Wave Biopharma Inc
$1.12
+0.9%
Global X Msci Next Emerging
$1.12
+0.9%
Fat Projects Acquisition Corp
$1.12
+0.9%
Capital Link Global Fintech
$1.12
+0.9%
Applied Uv Inc
$1.12
+0.9%